Home Tools

Deferoxamine Mesylate

Catalog No. T1637 CAS 138-14-7

Synonyms: desferrioxamine B, Desferrioxamine B mesylate, DFO, DFOM

Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Deferoxamine Mesylate Chemical Structure

Deferoxamine Mesylate, CAS 138-14-7

Pack Size	Availability	Price/USD
50 mg	In stock	$ 31.00
100 mg	In stock	$ 48.00
500 mg	In stock	$ 78.00
1 g	In stock	$ 113.00
1 mL * 10 mM (in DMSO)	In stock	$ 39.00

Bulk Inquiry

Select Batch

Purity: 99.8%

Purity: 99.65%

Purity: 99.45%

Purity: 99.18%

Purity: 99.13%

Purity: 99.04%

Purity: 98.52%

Purity: 98.34%

Purity: 98%

Purity: 94.68%

Biological Description

Chemical Properties

Storage & Solubility Information

Description	Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.
In vitro	METHODS: Human cervical cancer cells HeLa were treated with Deferoxamine Mesylate (3-100 μM) for 72 h, and cell numbers were detected using the Incucyte HD imaging system. RESULTS: Deferoxamine Mesylate inhibited cell growth in a concentration-dependent manner, and significant growth inhibition was observed at 100 μM. [1] METHODS: Human colorectal cancer cells HT29 and HCT116 were treated with Deferoxamine Mesylate (50-200 μM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Deferoxamine Mesylate induced significant expression of HIF-1α in a dose-dependent manner. [2] METHODS: Human breast cancer cells MDA-MB-231 and MCF-7 were treated with Deferoxamine Mesylate (200 μM) for 24 h. Apoptosis was detected by Flow Cytometry. RESULTS: After Deferoxamine Mesylate treatment, the apoptosis rate of MDA-MB-231 cells was unchanged compared with untreated cells, while apoptosis of MCF-7 cells was significantly increased. [3]
In vivo	METHODS: To investigate whether Deferoxamine Mesylate reduces inflammation and atherosclerosis in experimental mice, Deferoxamine Mesylate (100 mg/kg) was administered intraperitoneally to apolipoprotein E-deficient (apoE-/-) mice once a day for 10 weeks. RESULTS: Deferoxamine Mesylate reduced the development of aortic atherosclerotic lesions by 26% Deferoxamine Mesylate also reduced serum MCP-1 levels and gene expression of proinflammatory and macrophage markers in the aorta and heart, and increased protein expression of transferrin receptors in the heart and liver. In contrast, Deferoxamine Mesylate treatment had no effect on serum cholesterol and triglyceride levels. [4] METHODS: To study the effect of Deferoxamine Mesylate on adipocyte dysfunction in adipose tissue of ob/ob mice epididymis, Deferoxamine Mesylate (100 mg/kg) was injected intraperitoneally into ob/ob mice once daily for fifteen days. RESULTS: Deferoxamine Mesylate significantly improved important parameters of adipose tissue biology by decreasing the secretion of reactive oxygen species and inflammatory markers, by increasing the levels of antioxidant enzymes, HIF-1α, and HIF-1α-targeted proteins, and by altering adipocyte iron-, glucose-, and lipid-related metabolic proteins. Meanwhile, hypertrophic adipocytes were reduced in size and insulin signaling pathway-related proteins were activated after Deferoxamine Mesylate treatment. [5]
Cell Research	After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?μM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3].
Animal Research	The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group), immunohistochemistry (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4].

Synonyms	desferrioxamine B, Desferrioxamine B mesylate, DFO, DFOM
Molecular Weight	656.79
Formula	C26H52N6O11S
CAS No.	138-14-7

Storage

store at low temperature,keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 152.3 mM

H2O: 20.83 mg/mL (31.72 mM)

References and Literature

1. Fujisawa K, et al. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells. Cancer Metab. 2022 May 12;10(1):8. 2. Zhang W, et al. Deferoxamine enhances cell migration and invasion through promotion of HIF-1α expression and epithelial-mesenchymal transition in colorectal cancer. Oncol Rep. 2014 Jan;31(1):111-6. 3. Chen C, et al. Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism. Int J Mol Sci. 2019 Oct 8;20(19):4952. 4. Zhang WJ, et al. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010 May;235(5):633-41. 5. Yan HF, et al. Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice. Endocr Connect. 2018 Apr;7(4):604-616. 6. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e 8. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine-Based “Off–On” Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device[J]. ACS applied materials & interfaces. 2019, 11(46): 42873-42884. 9. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine Based “Off-On” Long-Circulating Assembly as Ferroptosis Amplifier for Cancer Treatment: a Lipid-Peroxidation Burst Device[J]. ACS applied materials & interfaces. 2019. 10. Wang S, Li F, Qiao R, et al. Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics[J]. ACS nano. 2018 Dec 26;12(12):12380-12392.

Citations

1. Bi G, Liang J, Shan G, et al.Retinol saturase mediates retinoid metabolism to impair a ferroptosis defense system in cancer cells.Cancer Research.2023: CAN-22-3977. 2. Zhu X, Huang N, Ji Y, et al.Brusatol induces ferroptosis in oesophageal squamous cell carcinoma by repressing GSH synthesis and increasing the labile iron pool via inhibition of the NRF2 pathway.Biomedicine & Pharmacotherapy.2023, 167: 115567. 3. Chen T, Leng J, Tan J, et al.Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.Journal of Medicinal Chemistry.2023 4. Zhao G, Liang J, Shan G, et al.KLF11 regulates lung adenocarcinoma ferroptosis and chemosensitivity by suppressing GPX4.Communications Biology.2023, 6(1): 570. 5. Liu J, Pan Z, Tong B, et al.Artesunate protects against ocular fibrosis by suppressing fibroblast activation and inducing mitochondria‐dependent ferroptosis.The FASEB Journal.2023, 37(6): e22954. 6. Li Y, Bao Y, Li Y, et al.RSL3 Inhibits Porcine Epidemic Diarrhea Virus Replication by Activating Ferroptosis.Viruses.2023, 15(10): 2080. 7. Gao X, Jiang P, Wei X, et al.Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.BMC cancer.2023, 23(1): 1-16. 8. Besskaya V, Zhang H, Bian Y, et al.Hepatic nuclear factor 4 alpha promotes the ferroptosis of lung adenocarcinoma via transcriptional activation of cytochrome P450 oxidoreductase.PeerJ.2023, 11: e15377. 9. Zhou Y, Wu H, Wang F, et al. GPX7 Is Targeted by miR-29b and GPX7 Knockdown Enhances Ferroptosis Induced by Erastin in Glioma. Frontiers in oncology. 2021, 11: 802124-802124. 10. Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Molecular Therapy-Nucleic Acids. 2022

11. Huang C Y, Chen L J, Chen G, et al. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2022, 23(19): 11092. 12. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine-Based “Off–On” Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device. ACS applied materials & interfaces. 2019, 11(46): 42873-42884. 13. Wang S, Li F, Qiao R, et al. Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics. ACS nano. 2018 Dec 26;12(12):12380-12392. 14. Fang Y, Tan Q, Zhou H, et al. Discovery and optimization of 2-(trifluoromethyl) benzimidazole derivatives as novel ferroptosis inducers in vitro and in vivo. European Journal of Medicinal Chemistry. 2022: 114905. 15. Lv Q, Niu H, Yue L, et al. Abnormal Ferroptosis in Myelodysplastic Syndrome. Frontiers in Oncology. 2020 Sep 2;10:1656 16. Deng F, Xu G, Cheng Z, et al. Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex. Frontiers in Immunology. 2021, 12: 233. 17. Liu Y, Li H, Luo Z, et al. Artesunate, a new antimalarial clinical drug, exhibits potent anti‐AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways. British Journal of Pharmacology. 2022 18. Sang M, Luo R, Bai Y, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019, 9(21): 6209. 19. Wu W Y, Wang Z X, Li T S, et al. SSBP1 drives high fructose-induced glomerular podocyte ferroptosis via activating DNA-PK/p53 pathway. Redox Biology. 2022: 102303. 20. Ouyang S, Li H, Lou L, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 2022: 102317 21. Li X, Wang H, Lu Z, et al. Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. Journal of Medicinal Chemistry. 2016 Sep 22;59(18):8326-44 22. Cheng Y, Qu W, Li J, et al. Ferristatin II, an Iron Uptake Inhibitor, Exerts Neuroprotection against Traumatic Brain Injury via Suppressing Ferroptosis. ACS Chemical Neuroscience. 2022 23. Shan G, Bi G, Zhao G, et al.Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer.Respiratory Research.2023, 24(1): 1-15. 24. Liu S, Tao Y, Wu S, et al.Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer.Chinese Medicine.2024, 19(1): 1-18. 25. Ying Z, Yin M, Zhu Z, et al.Iron Stress Affects the Growth and Differentiation of Toxoplasma gondii.International Journal of Molecular Sciences.2024, 25(5): 2493. 26. Bi G, Liang J, Bian Y, et al.Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer.Nature Communications.2024, 15(1): 2461.

See More... Hide

Related compound libraries

This product is contained In the following compound libraries：

Inhibitor Library Anti-Cancer Approved Drug Library Anti-Cancer Drug Library Anti-Neurodegenerative Disease Compound Library Anti-Cancer Clinical Compound Library Drug Repurposing Compound Library Anti-COVID-19 Compound Library FDA-Approved Drug Library Neuronal Signaling Compound Library Drug-induced Liver Injury (DILI) Compound Library

Related Products

Related compounds with same targets

Melatonin Liensinine Liensinine diperchlorate Simvastatin P62-mediated mitophagy inducer Ruxolitinib phosphate Curcumin Valproic acid sodium salt

Dose Conversion

You can also refer to dose conversion for different animals. More

In vivo Formulation Calculator (Clear solution)

Step One: Enter information below

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step Two: Enter the in vivo formulation

% DMSO+

% +

% Tween 80+

% ddH₂O

%DMSO+

Calculate Reset

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL)，Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation：Take μL DMSO master liquid, next add μL PEG300， mix and clarify, next add μL Tween 80，mix and clarify, next add μL ddH₂O, mix and clarify.

Note:

Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Calculator

Molarity Calculator

Dilution Calculator

Reconstitution Calculation

Molecular Weight Calculator

Mass

Concentration

Volume

Molecular Weight

Molarity Calculator allows you to calculate the

Mass of a compound required to prepare a solution of known volume and concentration
Volume of solution required to dissolve a compound of known mass to a desired concentration
Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Molecule Formula

Molecular Weight g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Deferoxamine Mesylate 138-14-7 Apoptosis Autophagy Chromatin/Epigenetic Metabolism Neuroscience Others HIF/HIF Prolyl-Hydroxylase Ferroptosis Beta Amyloid Mitophagy HIFs neovascularization TAMSCs desferrioxamine B diabetes mellitus Akt PKB Protein kinase B SH-SY5Y Hypoxia-inducible factors Deferoxamine Desferrioxamine B mesylate DFO Desferrioxamine B Mesylate Inhibitor MEFs cancer Alzheimer’s disease HIF-PH Reactive Oxygen Species BMMSCs inhibit DFOM COVID-19 inhibitor

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.